Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

As the first oral treatment for this condition, Rezdiffra's launch and market performance are crucial factors in determining the company's future success and stock performance. According to ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of $6.66 billion, has positioned itself as a frontrunner in the treatment of nonalcoholic steatohepatitis (NASH) with its ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

2. Madrigal’s Rezdiffra (resmetirom) for NASH/MASH Madrigal is turning biotech heads with its launch of NASH drug Rezdiffra, which notched an FDA approval March 14 as the first treatment for the liver ...

Since then, sales have been exploding. Revenues from the MASH drug Rezdiffra grew by over 400% from Q2 of this year to Q3. The $62 million in sales crushed consensus projections on Wall Street by 83%.

In early 2024, the FDA approved a new drug called Rezdiffra (resmetirom) for NASH, nonalcoholic steatohepatitis. How can you support your liver in menopause? You can support your liver in ...